Introduction: Cardiovascular diseases (CVD) are the most important cause of morbidity and mortality in type 2 diabetes (T2D). The objective of this study was to describe the profile of cardiovascular diseases of diabetics admitted at the cardiology departments of Aristide Le Dantec and Fann hospitals. Patients and Methods: This was a retrospective, descriptive and analytical study conducted on January 1st and December 31st, 2020 at the Dantec and Fann cardiology departments in Dakar. We studied epidemiological, diagnostic, therapeutic and evolutionary data. The data 7 was analyzed with STATA 14 software. Results: Of the 1483 patients hospitalized in both cardiology departments, one hundred and thirty-three (133) were diabetic, the hospital frequency was 9.01%. The average age was 62.3 ± 11.2 years. The sex ratio (M/F) was 0.8. Almost half (47.4%) of patients had a duration of diabetes greater than 10 years. Cardiovascular risk factors were dominated by physical inactivity (84.2%), menopause (81.9%) and hypertension (64.7%). Heart failure was the most common clinical manifestation with 45.1%. The prevalence of acute coronary artery disease in our study was 37.59%, followed by lower limbs peripheral arterial disease (9.7%) and stroke (3%). Concerning the treatment, 119 patients were on anti-diabetic treatment. Most patients were on aspirin (79%), cholesterol-lowering drugs (78.95%) and ACE inhibitor (77.44%). Percutaneous coronary intervention was performed in 19 patients. 12.03% of patients diabetics died during hospitalization. Conclusion: Cardiovascular events are common during type 2 diabetes. Their management is important to avoid complications that can be fatal.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.